Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490287 | 1.00 | CCR1 (0.80) | CCR1SMN1; SMN2MAPTNPC1TP53 | |
| SCHEMBL4500331 | 0.89 | CCR1 (1.00) | CCR1SMN1; SMN2MAPTTP53PANK3 | |
| SCHEMBL4500020 | 0.89 | CCR1 (1.00) | CCR1SMN1; SMN2MAPTTP53PANK3 | |
| SCHEMBL4485569 | 0.89 | CCR1 (0.73) | CCR1SMN1; SMN2MAPTNPC1TP53 | |
| SCHEMBL4485565 | 0.89 | CCR1 (0.73) | CCR1SMN1; SMN2MAPTNPC1TP53 | |
| SCHEMBL4501059 | 0.86 | CCR1 (0.60) | CCR1SMN1; SMN2MAPTTP53PANK3 | |
| SCHEMBL4501065 | 0.86 | CCR1 (0.60) | CCR1SMN1; SMN2MAPTTP53PANK3 | |
| SCHEMBL4506391 | 0.86 | CCR1 (0.85) | CCR1SMN1; SMN2MAPTTP53PANK3 | |
| SCHEMBL4506394 | 0.86 | CCR1 (0.85) | CCR1SMN1; SMN2MAPTTP53PANK3 | |
| SCHEMBL4496543 | 0.85 | CCR1 (0.84) | CCR1SMN1; SMN2MAPTTP53PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609664-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-1973880-B1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-7615556-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCR1 | CCR1 3/4885SMN1; SMN2 4822/4885MAPT 4559/4885 |
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCR1 | CCR1 3/4885SMN1; SMN2 4822/4885MAPT 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.